Baseline Uncommon EGFR Mutations in Non-Small-Cell Lung Cancer: Structure-Function Classification and Clinical Evidence Interpretation.

Authors

Susu Yang, Xiuqin Ma, Yongwei Zhao, Jinhua Ma

Published in

Cancer control : journal of the Moffitt Cancer Center. Volume 33. Pages 10732748261481943. Epub Sep 08, 2026.

Abstract

In this narrative review, we examine baseline uncommon epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) through a structure-function classification framework and clinical evidence interpretation. Baseline uncommon EGFR mutations are molecularly heterogeneous, and exon-based classification alone cannot fully capture their structural diversity or variable sensitivity to EGFR-targeted therapy. By relating kinase-domain conformation to therapeutic sensitivity, structure-function classification offers a biologically grounded lens for interpreting this heterogeneity alongside sequence-based classification. This review focuses on baseline uncommon EGFR mutations, including EGFR exon 20 insertion (ex20ins) mutations, P-loop and αC-helix-compressing (PACC) mutations, and classical-like and long-tail non-ex20ins variants, while distinguishing them from acquired resistance alterations after EGFR tyrosine kinase inhibitor (EGFR-TKI) exposure. Typical loop-region ex20ins mutations can impose steric constraints near the ATP-binding pocket and are generally associated with limited activity of conventional EGFR-TKIs. Among ex20ins-directed approaches, amivantamab plus carboplatin-pemetrexed chemotherapy is supported by mature randomized first-line evidence in approved and accessible settings; oral ex20ins-directed EGFR-TKIs require interpretation according to treatment line, regulatory context, study design, and follow-up maturity. For PACC mutations, EGFR-TKI activity has been reported mainly in selected recurrent variants, whereas evidence remains uneven across agents, variants, compound mutations, and less common PACC-related alterations. Among classical-like and long-tail non-ex20ins variants, L861Q illustrates how clinically defined cohorts may combine mutations with distinct structural and pharmacologic profiles, whereas long-tail alterations remain dependent on limited variant-level evidence. Overall, the evidence base remains heterogeneous, spanning randomized trials, single-arm studies, retrospective cohorts, real-world datasets, conference abstracts, and early clinical reports. Taken together, the evidence supports a structure-informed approach to baseline uncommon EGFR-mutant NSCLC, while treatment interpretation and clinical application should remain grounded in evidence level, clinical context, and treatment availability. Prospective subtype-stratified studies, consistent evidence grading, and standardized molecular reporting with structure-informed annotations are needed to improve clinical interpretation and inform treatment strategies.

PMID:
42711860
Bibliographic data and abstract were imported from PubMed on 09 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.